Cardinal Health Proxy: Director Elections & Executive Pay
Ticker: CAH · Form: DEF 14A · Filed: Sep 16, 2024 · CIK: 721371
| Field | Detail |
|---|---|
| Company | Cardinal Health INC (CAH) |
| Form Type | DEF 14A |
| Filed Date | Sep 16, 2024 |
| Risk Level | medium |
| Pages | 14 |
| Reading Time | 17 min |
| Key Dollar Amounts | $92 million, $240 million, $3.8 billion, $1.25 billion, $226.8 b |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, board-nominees, executive-compensation, shareholder-engagement
Related Tickers: CAH
TL;DR
CAH proxy out: vote directors & exec pay. Elliott deal mentioned.
AI Summary
Cardinal Health, Inc. filed its definitive proxy statement for its 2024 Annual Meeting of Shareholders, scheduled for September 13, 2024. The filing details the election of directors, executive compensation, and highlights the company's fiscal year 2024 performance and strategic priorities. Notably, it mentions an agreement with Elliott, indicating a significant shareholder engagement or resolution.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on board composition and executive compensation, impacting the company's future direction and governance.
Risk Assessment
Risk Level: medium — Proxy statements can signal shifts in corporate strategy, executive compensation, or board composition, which may influence investor sentiment and stock performance.
Key Players & Entities
- Cardinal Health, Inc. (company) — Registrant
- Elliott (company) — Shareholder engagement
- September 13, 2024 (date) — Annual Meeting date
FAQ
What are the key proposals shareholders will vote on at the Annual Meeting?
Shareholders will vote on the election of directors (Proposal 1) and an advisory vote to approve the compensation of Named Executive Officers (Proposal 2).
When is the Cardinal Health Annual Meeting of Shareholders?
The Annual Meeting of Shareholders is scheduled for September 13, 2024.
What is the significance of the mention of an 'Agreement with Elliott'?
The filing mentions an 'Agreement with Elliott' under the 'Shareholder Engagement' section, suggesting a resolution or collaboration with the activist investor firm.
What information is provided regarding executive compensation?
The filing includes a Compensation Discussion and Analysis section and an advisory vote to approve the compensation of Named Executive Officers.
What are Cardinal Health's stated strategic priorities?
The filing outlines Cardinal Health's strategic priorities, though specific details are not provided in the excerpt, it is a key section for shareholders.
Filing Stats: 4,339 words · 17 min read · ~14 pages · Grade level 14.1 · Accepted 2024-09-16 16:12:06
Key Financial Figures
- $92 million — profit 7%, while GMPD segment profit of $92 million was an almost $240 million year-over-ye
- $240 million — ent profit of $92 million was an almost $240 million year-over-year improvement. We also gen
- $3.8 billion — r improvement. We also generated nearly $3.8 billion of operating cash flow, which positione
- $1.25 billion — ash flow, which positioned us to return $1.25 billion to shareholders through share repurchas
- $226.8 b — reinvestment of dividends. Revenue was $226.8 billion, up 11% from the prior year. GAA
- $1.2 b — ior year. GAAP operating earnings were $1.2 billion, which included $675 million in p
- $675 million — nings were $1.2 billion, which included $675 million in pre-tax goodwill impairment charges
- $2.4 b — gment. Non-GAAP operating earnings were $2.4 billion, a 16% increase over the prior ye
- $3 — diluted earnings per share ("EPS") were $3.45, which included the pre-tax goodwill
- $617 million — he pre-tax goodwill impairment charges ($617 million after tax or $2.50 per share) related t
- $2.50 — ment charges ($617 million after tax or $2.50 per share) related to the GMPD segment.
- $7 — GMPD segment. Non-GAAP diluted EPS was $7.53, a 29% increase over the prior yea
- $750 million — n to shareholders in share repurchases ($750 million) and dividends ($499 million), and inve
- $499 million — purchases ($750 million) and dividends ($499 million), and invested over $500 million back i
- $500 million — dends ($499 million), and invested over $500 million back into our businesses to drive organ
Filing Documents
- cah-20240913.htm (DEF 14A) — 1976KB
- a4329631_53xcardinalhealth.pdf (DEF 14A) — 5730KB
- cah-20240913_g1.jpg (GRAPHIC) — 21KB
- cah-20240913_g10.jpg (GRAPHIC) — 24KB
- cah-20240913_g100.jpg (GRAPHIC) — 564KB
- cah-20240913_g101.jpg (GRAPHIC) — 564KB
- cah-20240913_g102.jpg (GRAPHIC) — 15KB
- cah-20240913_g103.jpg (GRAPHIC) — 32KB
- cah-20240913_g104.jpg (GRAPHIC) — 33KB
- cah-20240913_g105.jpg (GRAPHIC) — 147KB
- cah-20240913_g106.jpg (GRAPHIC) — 33KB
- cah-20240913_g107.jpg (GRAPHIC) — 136KB
- cah-20240913_g108.jpg (GRAPHIC) — 35KB
- cah-20240913_g109.jpg (GRAPHIC) — 175KB
- cah-20240913_g11.jpg (GRAPHIC) — 21KB
- cah-20240913_g110.jpg (GRAPHIC) — 41KB
- cah-20240913_g111.jpg (GRAPHIC) — 44KB
- cah-20240913_g112.jpg (GRAPHIC) — 43KB
- cah-20240913_g113.jpg (GRAPHIC) — 41KB
- cah-20240913_g114.jpg (GRAPHIC) — 40KB
- cah-20240913_g115.jpg (GRAPHIC) — 41KB
- cah-20240913_g116.jpg (GRAPHIC) — 42KB
- cah-20240913_g117.jpg (GRAPHIC) — 42KB
- cah-20240913_g118.jpg (GRAPHIC) — 40KB
- cah-20240913_g119.jpg (GRAPHIC) — 5KB
- cah-20240913_g12.jpg (GRAPHIC) — 21KB
- cah-20240913_g120.jpg (GRAPHIC) — 134KB
- cah-20240913_g121.jpg (GRAPHIC) — 5KB
- cah-20240913_g122.jpg (GRAPHIC) — 5KB
- cah-20240913_g123.jpg (GRAPHIC) — 5KB
- cah-20240913_g124.jpg (GRAPHIC) — 33KB
- cah-20240913_g125.jpg (GRAPHIC) — 302KB
- cah-20240913_g126.jpg (GRAPHIC) — 33KB
- cah-20240913_g127.jpg (GRAPHIC) — 103KB
- cah-20240913_g128.jpg (GRAPHIC) — 112KB
- cah-20240913_g129.jpg (GRAPHIC) — 34KB
- cah-20240913_g13.jpg (GRAPHIC) — 22KB
- cah-20240913_g130.jpg (GRAPHIC) — 54KB
- cah-20240913_g131.jpg (GRAPHIC) — 31KB
- cah-20240913_g132.jpg (GRAPHIC) — 55KB
- cah-20240913_g133.jpg (GRAPHIC) — 31KB
- cah-20240913_g134.jpg (GRAPHIC) — 53KB
- cah-20240913_g135.jpg (GRAPHIC) — 33KB
- cah-20240913_g136.jpg (GRAPHIC) — 36KB
- cah-20240913_g137.jpg (GRAPHIC) — 30KB
- cah-20240913_g138.jpg (GRAPHIC) — 33KB
- cah-20240913_g139.jpg (GRAPHIC) — 37KB
- cah-20240913_g14.jpg (GRAPHIC) — 21KB
- cah-20240913_g140.jpg (GRAPHIC) — 32KB
- cah-20240913_g141.jpg (GRAPHIC) — 54KB
- cah-20240913_g142.jpg (GRAPHIC) — 56KB
- cah-20240913_g143.jpg (GRAPHIC) — 54KB
- cah-20240913_g144.jpg (GRAPHIC) — 51KB
- cah-20240913_g145.jpg (GRAPHIC) — 54KB
- cah-20240913_g146.jpg (GRAPHIC) — 125KB
- cah-20240913_g147.jpg (GRAPHIC) — 209KB
- cah-20240913_g148.jpg (GRAPHIC) — 13KB
- cah-20240913_g149.jpg (GRAPHIC) — 557KB
- cah-20240913_g15.jpg (GRAPHIC) — 21KB
- cah-20240913_g150.jpg (GRAPHIC) — 557KB
- cah-20240913_g151.jpg (GRAPHIC) — 13KB
- cah-20240913_g152.jpg (GRAPHIC) — 12KB
- cah-20240913_g153.jpg (GRAPHIC) — 206KB
- cah-20240913_g154.jpg (GRAPHIC) — 194KB
- cah-20240913_g155.jpg (GRAPHIC) — 32KB
- cah-20240913_g156.jpg (GRAPHIC) — 29KB
- cah-20240913_g157.jpg (GRAPHIC) — 1768KB
- cah-20240913_g158.jpg (GRAPHIC) — 796KB
- cah-20240913_g159.jpg (GRAPHIC) — 744KB
- cah-20240913_g16.jpg (GRAPHIC) — 32KB
- cah-20240913_g17.jpg (GRAPHIC) — 16KB
- cah-20240913_g18.jpg (GRAPHIC) — 34KB
- cah-20240913_g19.jpg (GRAPHIC) — 16KB
- cah-20240913_g2.jpg (GRAPHIC) — 1726KB
- cah-20240913_g20.jpg (GRAPHIC) — 14KB
- cah-20240913_g21.jpg (GRAPHIC) — 14KB
- cah-20240913_g22.jpg (GRAPHIC) — 42KB
- cah-20240913_g23.jpg (GRAPHIC) — 128KB
- cah-20240913_g24.jpg (GRAPHIC) — 15KB
- cah-20240913_g25.jpg (GRAPHIC) — 16KB
- cah-20240913_g26.jpg (GRAPHIC) — 103KB
- cah-20240913_g27.jpg (GRAPHIC) — 130KB
- cah-20240913_g28.jpg (GRAPHIC) — 14KB
- cah-20240913_g29.jpg (GRAPHIC) — 14KB
- cah-20240913_g3.jpg (GRAPHIC) — 62KB
- cah-20240913_g30.jpg (GRAPHIC) — 143KB
- cah-20240913_g31.jpg (GRAPHIC) — 41KB
- cah-20240913_g32.jpg (GRAPHIC) — 88KB
- cah-20240913_g33.jpg (GRAPHIC) — 80KB
- cah-20240913_g34.jpg (GRAPHIC) — 97KB
- cah-20240913_g35.jpg (GRAPHIC) — 36KB
- cah-20240913_g36.jpg (GRAPHIC) — 34KB
- cah-20240913_g37.jpg (GRAPHIC) — 28KB
- cah-20240913_g38.jpg (GRAPHIC) — 29KB
- cah-20240913_g39.jpg (GRAPHIC) — 37KB
- cah-20240913_g4.jpg (GRAPHIC) — 38KB
- cah-20240913_g40.jpg (GRAPHIC) — 41KB
- cah-20240913_g41.jpg (GRAPHIC) — 33KB
- cah-20240913_g42.jpg (GRAPHIC) — 30KB
- cah-20240913_g43.jpg (GRAPHIC) — 40KB
- cah-20240913_g44.jpg (GRAPHIC) — 38KB
- cah-20240913_g45.jpg (GRAPHIC) — 28KB
- cah-20240913_g46.jpg (GRAPHIC) — 30KB
- cah-20240913_g47.jpg (GRAPHIC) — 40KB
- cah-20240913_g48.jpg (GRAPHIC) — 27KB
- cah-20240913_g49.jpg (GRAPHIC) — 25KB
- cah-20240913_g5.jpg (GRAPHIC) — 323KB
- cah-20240913_g50.jpg (GRAPHIC) — 27KB
- cah-20240913_g51.jpg (GRAPHIC) — 30KB
- cah-20240913_g52.jpg (GRAPHIC) — 89KB
- cah-20240913_g53.jpg (GRAPHIC) — 88KB
- cah-20240913_g54.jpg (GRAPHIC) — 90KB
- cah-20240913_g55.jpg (GRAPHIC) — 35KB
- cah-20240913_g56.jpg (GRAPHIC) — 36KB
- cah-20240913_g57.jpg (GRAPHIC) — 33KB
- cah-20240913_g58.jpg (GRAPHIC) — 34KB
- cah-20240913_g59.jpg (GRAPHIC) — 33KB
- cah-20240913_g6.jpg (GRAPHIC) — 61KB
- cah-20240913_g60.jpg (GRAPHIC) — 34KB
- cah-20240913_g61.jpg (GRAPHIC) — 33KB
- cah-20240913_g62.jpg (GRAPHIC) — 33KB
- cah-20240913_g63.jpg (GRAPHIC) — 37KB
- cah-20240913_g64.jpg (GRAPHIC) — 36KB
- cah-20240913_g65.jpg (GRAPHIC) — 16KB
- cah-20240913_g66.jpg (GRAPHIC) — 66KB
- cah-20240913_g67.jpg (GRAPHIC) — 36KB
- cah-20240913_g68.jpg (GRAPHIC) — 40KB
- cah-20240913_g69.jpg (GRAPHIC) — 34KB
- cah-20240913_g7.jpg (GRAPHIC) — 25KB
- cah-20240913_g70.jpg (GRAPHIC) — 38KB
- cah-20240913_g71.jpg (GRAPHIC) — 37KB
- cah-20240913_g72.jpg (GRAPHIC) — 39KB
- cah-20240913_g73.jpg (GRAPHIC) — 41KB
- cah-20240913_g74.jpg (GRAPHIC) — 14KB
- cah-20240913_g75.jpg (GRAPHIC) — 73KB
- cah-20240913_g76.jpg (GRAPHIC) — 15KB
- cah-20240913_g77.jpg (GRAPHIC) — 66KB
- cah-20240913_g78.jpg (GRAPHIC) — 128KB
- cah-20240913_g79.jpg (GRAPHIC) — 56KB
- cah-20240913_g8.jpg (GRAPHIC) — 25KB
- cah-20240913_g80.jpg (GRAPHIC) — 15KB
- cah-20240913_g81.jpg (GRAPHIC) — 65KB
- cah-20240913_g82.jpg (GRAPHIC) — 16KB
- cah-20240913_g83.jpg (GRAPHIC) — 74KB
- cah-20240913_g84.jpg (GRAPHIC) — 103KB
- cah-20240913_g85.jpg (GRAPHIC) — 57KB
- cah-20240913_g86.jpg (GRAPHIC) — 131KB
- cah-20240913_g87.jpg (GRAPHIC) — 57KB
- cah-20240913_g88.jpg (GRAPHIC) — 14KB
- cah-20240913_g89.jpg (GRAPHIC) — 56KB
- cah-20240913_g9.jpg (GRAPHIC) — 28KB
- cah-20240913_g90.jpg (GRAPHIC) — 143KB
- cah-20240913_g91.jpg (GRAPHIC) — 73KB
- cah-20240913_g92.jpg (GRAPHIC) — 565KB
- cah-20240913_g93.jpg (GRAPHIC) — 565KB
- cah-20240913_g94.jpg (GRAPHIC) — 564KB
- cah-20240913_g95.jpg (GRAPHIC) — 563KB
- cah-20240913_g96.jpg (GRAPHIC) — 568KB
- cah-20240913_g97.jpg (GRAPHIC) — 563KB
- cah-20240913_g98.jpg (GRAPHIC) — 562KB
- cah-20240913_g99.jpg (GRAPHIC) — 564KB
- 0000721371-24-000103.txt ( ) — 56983KB
- cah-20240913.xsd (EX-101.SCH) — 2KB
- cah-20240913_def.xml (EX-101.DEF) — 3KB
- cah-20240913_lab.xml (EX-101.LAB) — 3KB
- cah-20240913_pre.xml (EX-101.PRE) — 2KB
- cah-20240913_htm.xml (XML) — 149KB
Forward-Looking Statements
Forward-Looking Statements 13 CORPORATE GOVERNANCE 14 PROPOSAL 1 — Election of Directors 14 Board Membership Criteria: What We Look For 14 Our Director Nominees 15 Our Board's Composition and Structure 26 Our Board's Primary Role , Responsibilities , and Processes 35 Shareholder Engagement 40 Standards of Business Conduct 41 Related Person Transactions Policy and Process 41 Director Compensation 42
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 44 PROPOSAL 2 — Advisory Vote to Approve the Compensation of Our Named Executive Officers 45 Compensation Discussion and Analysis 46 Human Resources and Compensation Committee Report 62
Executive Compensation Tables
Executive Compensation Tables 63 Pay Ratio Disclosure 76 Pay Versus Performance 77 Equity Compensation Plan Information 81 AUDIT COMMITTEE MATTERS 82 PROPOSAL 3 — Ratification of Appointment of Ernst & Young LLP as Independent Auditor 82 Audit Committee Report 82 Fees Paid to Ernst & Young LLP 83 Policy on Pre-Approval of Services Provided by Ernst & Young LLP 83 SHAREHOLDER PROPOSALS 84 PROPOSAL 4 — Shareholder Proposal to Prohibit the Re- n omination of Any Director Who Fails to Receive a Majority Vote 84 SHARE OWNERSHIP INFORMATION 86 OTHER MATTERS 87 General Information About the Annual Meeting 87 Communicating with the Board 89 Shareholder Recommendations for Director Nominees 90 Submitting Proxy Proposals and Director Nominations for the Next Annual Meeting of Shareholders 90 Corporate Governance Documents 91 Transfer Agent 91 ANNEX A: USE OF NON-GAAP FINANCIAL MEASURES A- 1 Exclusions from Non-GAAP Financial Measures A- 1 Fiscal 202 4 GAAP to Non-GAAP Reconciliations A- 2 Definitions A- 2 CARDINAL HEALTH 2024 Proxy Statement 1 LETTER TO CARDINAL HEALTH SHAREHOLDERS SEPTEMBER 16, 2024 Fiscal 2024 was a year of strong financial performance at Cardinal Health, delivered in tandem with key strategic progress in the portfolio. We finished the year with continued momentum, and the Board and management team are working together to advance our strategy to maximize shareholder value creation. CONTINUED STRATEGIC FOCUS ON MAXIMIZING SHAREHOLDER VALUE We continue to advance our strategy to build upon the growth and resiliency of the Pharmaceutical and Specialty Solutions segment, execute our Global Medical Products and Distribution ("GMPD") Improvement Plan, and accelerate our growth in key areas, while optimizing our portfolio to maximize shareholder value creation. This year we took decisive actions to simplify our business and drive performance, including reorganizing our operating and segmen